Shane Todd Marshall Eleniak - 12 Feb 2026 Form 4 Insider Report for CALIX, INC ((CALX))

Role: Chief Product Officer
Signature: /s/ Tom Gemetti as Attorney-in-fact for Shane Eleniak
Issuer symbol: (CALX)
Transactions as of: 12 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Feb 2026, 16:04:56 UTC
Previous filing: 12 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Eleniak Shane Todd Marshall	Chief Product Officer	C/O CALIX, INC., 3155 OLSEN DRIVE, SUITE 450, SAN JOSE	/s/ Tom Gemetti as Attorney-in-fact for Shane Eleniak	17 Feb 2026	0001886143

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	(CALX)	Stock Option	Award	$0	+195,000		$0.000000	195,000	12 Feb 2026	Common Stock	195,000	$39.68	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 31, 2025, the reporting person was granted a performance-based option to purchase 195,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.

Content

On January 31, 2025, the reporting person was granted a performance-based option to purchase 195,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.